What Локоид Treats: Main Uses and Benefits

Локоид (Hydrocortisone Butyrate) is a medium-potency topical steroid commonly used for providing focused symptomatic support across various inflammatory skin conditions. This medication is relevant in conditions involving episodic or fluctuating manifestations, such as Atopic Dermatitis (Eczema), Plaque Psoriasis, and different forms of Contact Dermatitis, and is used for managing symptoms that become more disruptive during flare-ups.

The treatment is applied across domains where additional symptomatic support is needed, primarily to address redness (erythema), localized swelling, and persistent itching (pruritus). It contributes to improved comfort during these periods of heightened symptoms, offering supportive relief and contributing to easing the overall symptom load. It is also applicable within clinical settings that involve acute or unstable symptom patterns in specific areas, such as Seborrheic Dermatitis of the scalp.

“The symptomatic relief provided by this medication may assist with easing distress during difficult episodes.”

---

Quick Fact: Symptomatic Support for Inflammation and Pruritus

Regulatory References

1. NIH DailyMed drug label

Who Can and Cannot Use Локоид? (Population Eligibility)

The use of Локоид (Hydrocortisone Butyrate) is defined by official regulatory criteria that determine patient eligibility based on age, existing conditions, and physiological status.

Contraindications and Non-Eligibility

Contraindicated populations must not use this medicine. These include patients with a known hypersensitivity to the active ingredient or excipients, or those with specific untreated skin infections, such as viral (e.g., Herpes Simplex), fungal, mycotic, or parasitic infections. Furthermore, use is prohibited in areas affected by conditions such as rosacea, acne vulgaris, peri-oral dermatitis, or ulcerous skin lesions, as stated in the Summary of Product Characteristics (SmPC) across various regions.

Age and Conditional Use Rules

Population Group	Regulatory Status and Limitation
Infants/Children	Not indicated for those under 3 months of age. Children are more susceptible to systemic toxicity; use in infants should be limited to a maximum of seven days, where possible.
Adults/Older Adults	Use is permitted under standard labeled conditions, with no specific dosage regimen indicated for older adults.
Pregnancy (Category C)	Use is conditional: only if the potential benefit justifies the potential risk to the fetus. Prolonged or extensive use is not recommended.
Lactation	Generally acceptable, but advised to avoid applying directly to the breast or to wash off the product before nursing.

Restrictions on Application

Official labeling advises against or restricts use on the face, groin, or underarms due to heightened absorption risk. Application using occlusive dressings (including diapers) must also be avoided unless specifically instructed by a physician.

Interactions with other medicines and products

The official regulatory profile for Локоид (Hydrocortisone Butyrate), a medium-potency topical corticosteroid, is defined by its low systemic absorption following cutaneous application. The specific regulatory labeling indicates a general absence of formal, clinically significant drug-drug or substance interactions.

---

Regulatory Interaction Status

Official documents confirm there are no specific medicinal products formally listed as contraindicated for co-administration with Locoid. Consistent with this, the prescribing information documents no specific pharmacokinetic (PK) or pharmacodynamic (PD) interactions involving metabolic enzymes or drug transporters. This means there are no mandated timing rules or separation requirements for administration with other medicines, food, alcohol, or supplements.

Population-Specific Caution

The primary constraint noted in regulatory documents relates to a specific patient condition, rather than an external substance. Liver failure (hepatic impairment) is explicitly documented as a factor that may predispose an individual to increased systemic absorption of the active ingredient. This heightened systemic exposure in patients with compromised liver function elevates the potential risk for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a known effect of the corticosteroid class. The official interaction profile is thus focused on this internal physiological risk associated with hepatic status.

How Локоид Works

The mechanism of Hydrocortisone Butyrate involves the local modulation of the inflammatory and immune response in the skin, engaging systems that affect cellular physiological processes. Its action relies on a comprehensive three-part cascade.

---

Targeting the Glucocorticoid Receptor and Genetic Control

The drug initiates its effect by acting as an agonist on the Glucocorticoid Receptor ( GR) inside skin cells. This binding and activation lead to a profound genomic action: both transactivation (turning on anti-inflammatory genes like Lipocortin-1) and transrepression (turning off pro-inflammatory genes regulated by NF-kappa B). This mechanism primarily influences the cell's capacity to generate inflammatory signals, contributing to the overall modulation of local physiological activity.

---

Blockade of Inflammatory Mediator Cascades

The activated genetic program results in the synthesis of proteins that enforce a targeted blockade of key biochemical pathways, specifically inhibiting the enzyme Phospholipase A2 ( PLA2). This step restricts the release of Arachidonic Acid, the precursor required to synthesize major inflammatory mediators such as Prostaglandins and Leukotrienes, thereby reducing the local concentration of these potent signaling molecules.

---

Physiological Modulation of Vascular Tone and Cell Traffic

Beyond its direct molecular effects, the mechanism produces observable physiological changes by causing vasoconstriction (narrowing of local blood vessels) and suppressing the infiltration and function of immune cells (macrophages and T-lymphocytes) in the applied area. This physical containment of the response constricts local blood vessels, limiting the extravasation of fluid and proteins into the tissue and driving the observable physiological changes associated with decreased local edema and erythema.

Locoid (Hydrocortisone Butyrate) is approved for administration exclusively via the topical (cutaneous) route and is not to be used orally, ophthalmicly, or intravaginally. This medium-potency topical steroid is supplied in several forms, including a cream, lotion, and ointment, consistently formulated at a 0.1% concentration. The proper administration method requires applying a thin layer of the preparation and rubbing it in gently over the affected skin area only.

The standard application frequency for adult use for corticosteroid-responsive dermatoses typically ranges from one to three times daily, depending on the specific formulation and regional prescribing information. For pediatric patients aged 3 months and older, the official regimen for conditions like atopic dermatitis often involves application two times daily (BID). The course duration for infants is often limited to a maximum of seven days.

The guiding principle for its use is that application must be discontinued immediately once control of the skin condition is achieved. Continuous use is generally limited, and treatment should be reassessed by a medical professional if no observable improvement occurs within two weeks; efficacy is usually not established beyond four weeks of continuous use. Specific procedural instructions require avoiding application to the face, groin, and underarm areas unless explicitly directed, and the product must not be used under occlusive dressings, including tight-fitting diapers, as this modifies the administration context.

Research Evidence / Overview of Studies for Локоид

This section provides an overview of the types of research and clinical trials that have evaluated the active ingredient in Локоид, Hydrocortisone Butyrate. The information focuses strictly on the evidence landscape and what the studies monitored, without providing clinical advice or making claims about individual outcomes.

---

Evidence Base for Atopic Dermatitis (Eczema)

Clinical evaluation for Atopic Dermatitis, a condition characterized by fluctuating and episodic manifestations, primarily involves short-term Randomized Controlled Trials (RCTs). These studies were designed to compare the effects observed with the active medicine against a non-medicated vehicle (placebo) or against other active, established topical corticosteroids.

Research examined outcomes related to physical discomfort and inflammatory states, such as measured changes in overall disease severity scores (like the Investigator Global Assessment - IGA) and the intensity of specific signs, including pruritus (itching) and redness. The studies were conducted during periods of increased symptom activity and generally included adults and specific pediatric populations, with some trials monitoring children as young as 3 months of age.

Findings report patterns observed in the studies, which documented the measured changes in the severity of disease scores and individual symptoms over the short observation periods, typically lasting two to four weeks. Specialized trials also focused on physiological strain by monitoring the hypothalamic-pituitary-adrenal (HPA) axis function, an outcome related to systemic imbalance, in the observed populations.

Evidence Base for Psoriasis and Chronic Dermatitis

Research has explored the use of this compound in managing Psoriasis and various forms of chronic dermatitis, which are conditions marked by inflammatory and irritative states. Studies in this area often took the form of comparative clinical trials, where the medicine was evaluated against other topical steroid preparations.

---

Long-Term Evidence and Observation Durations

The majority of pivotal studies for the topical corticosteroid class were conducted with a short-term follow-up duration, often ranging from two to four weeks. This is a common practice in research exploring changes during acute or episodic symptom activity.

This means that the long-term outcomes and durability of measured changes on chronic disease course are not fully established by the existing efficacy research. Studies focusing on extended use often center on monitoring specific physiological markers rather than continuous efficacy over many months.

Studies in Specific Patient Groups

Research indicates patterns in which specific patient groups have been the focus of dedicated studies. Most notably, the medicine was evaluated in pediatric populations (infants and children), where studies were designed to monitor systemic or functional imbalance outcomes.

Furthermore, studies have examined patient-reported outcomes describing pruritus in adults with various inflammatory conditions. However, results apply only to the specific populations studied, and data for certain groups, such as older adults or those with multiple comorbidities, remain insufficient or limited.

Gaps in the Research and Areas of Uncertainty

A review of the research indicates several areas where data remain insufficient or where certainty remains low.

Follow-up durations were limited in many of the core efficacy trials, meaning long-term effects and the management of symptom relapse in chronic conditions are not yet fully established by the evidence. Findings describe group patterns, not personal outcomes, as study results reflect the specific conditions and patient groups under which they were conducted. Research is ongoing to address some of these knowledge gaps.

Key Studies & References

1. Label: HYDROCORTISONE BUTYRATE cream - DailyMed (NIH)
2. Label: HYDROCORTISONE BUTYRATE lotion - DailyMed (NIH)

Common questions about Локоид (FAQ)

---

Q: What kind of skin conditions is Локоид officially used for?

The medicine is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. According to official documents, this includes commonly studied conditions such as atopic dermatitis (eczema) and psoriasis.

Q: How does Локоид differ from other steroid creams I have heard of?

Official information classifies the active ingredient in Локоид, which is hydrocortisone butyrate, as a medium-potency topical corticosteroid. The active substance is chemically a specialized synthetic derivative of hydrocortisone. This classification places it within a specific category relative to other topical steroid preparations.

Q: Is Локоид prescribed for children?

The drug is officially indicated for use in pediatric patients aged 3 months and older for certain conditions, such as mild to moderate atopic dermatitis. The use in infants younger than 3 months is typically determined by a healthcare provider.

Q: How long does it typically take to see a noticeable change when using Локоид?

Regulatory guidance advises that a reassessment by a healthcare professional is needed if there is no observable improvement in the condition within two weeks of starting therapy. This regulatory threshold suggests that reassessment is advised if no measurable response has been documented within the two-week period.

Q: Are there known issues with applying makeup or cosmetics over Локоид?

The official product label advises against using cosmetics or other skin care products on the specific areas being treated. The restriction helps ensure the topical preparation is applied to the affected skin as intended.

Q: What happens if I stop using Локоид suddenly?

Treatment is officially intended to be discontinued when control of the condition is achieved. Rapid cessation of long-term or widespread continuous topical corticosteroid use may be associated with symptoms of a Topical Corticosteroid Withdrawal reaction.

Q: Is it possible to develop a dependency on Локоид?

The term 'dependency' is not used in regulatory sources. However, official documents contain warnings about Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a systemic effect. These effects are associated with the prolonged use of topical corticosteroids.

Q: Do official sources mention using Локоид for eczema?

Yes, official documents explicitly list atopic dermatitis (eczema) as an indicated use for the medicine.

Q: Is there a risk of skin thinning (atrophy) with the use of Локоид?

Yes, skin atrophy (thinning) is an officially documented side effect, often listed as uncommon. Regulatory safety statements associate this risk primarily with prolonged or extended use of the medicine.

Q: Is it described as being suitable for use during pregnancy in official documents?

The FDA classifies the drug as Pregnancy Category C. Official documents state that it should be used during pregnancy only if the potential benefit is determined to justify the potential risk to the fetus. The labeling advises against extensive or prolonged use during pregnancy.

Q: What is the recommended period of time to wait between applications of Локоид and other products?

Official patient information suggests that if a moisturizer is used alongside the preparation, the moisturizer should be applied first. A waiting period, often cited as 10 to 15 minutes, is generally recommended before applying the steroid preparation.

Q: Are there specific patient groups (e.g., diabetics) who need special consideration when using Локоид, according to official warnings?

Yes, regulatory documents explicitly note a caution for patients with liver failure (hepatic impairment). Systemic effects can include changes like hyperglycemia (high blood sugar), which are relevant considerations for patients with conditions like diabetes. This is noted as an area for careful consideration.

Q: Why is it important not to exceed the recommended duration of use for Локоид?

Exceeding the recommended duration significantly increases the risk of documented side effects. This includes both local effects, such as skin atrophy, and systemic effects, such as HPA-axis suppression (adrenal function issues) and Cushing's syndrome.

Q: How does the concentration of the active ingredient in Локоид compare to other similar products?

The drug is consistently formulated at a 0.1% concentration of hydrocortisone butyrate. Regulatory bodies classify this formulation as a medium-potency topical corticosteroid. Healthcare professionals generally rely on the potency classification rather than the percentage strength for comparison purposes.

Q: Can Локоид be used on the face, according to official documents?

The product label advises against use on the face, underarms, or groin areas due to the heightened risk of absorption and side effects. Use on these sensitive areas is typically reserved for cases where it has been explicitly directed by a healthcare provider.

Q: What happens if an application is missed?

The Patient Information Leaflet (PIL) provides specific guidance for handling a missed application, advising against applying extra product. Consult the 'How to Use' section for detailed instructions.

Q: Can Локоид be used for itchiness that is not related to the listed conditions?

Regulatory guidance states that the medicine should only be used for the skin condition for which it was prescribed. It is not intended for other types of itchiness, especially if a patient suspects they may have a skin infection.

Q: Is the vehicle (cream vs. ointment) described as affecting the drug's action?

Regulatory documents mention that different formulations, such as cream, lotion, or ointment, are available to suit various skin conditions and anatomical locations. Clinical trials often specify the type of vehicle used, indicating it is a factor in how the drug is evaluated.

Q: What are the risks if Локоид is accidentally applied to the eye?

The product is not for ophthalmic use, and contact with the eyes should be avoided. Topical corticosteroids, when applied near or in the eyes, may increase the risk of conditions like cataracts and glaucoma. Patients are advised to report any visual symptoms if accidental exposure occurs.

Q: What are the official instructions if the product is frozen or exposed to high heat?

The product must be stored at a controlled room temperature between 20 C and 25 C (68 F and 77 F). Patients are specifically instructed in the labeling not to freeze the product to maintain its stability.

Q: What do official sources say about reapplying Локоид after washing the hands or area?

Official patient instructions recommend that after applying the medicine, it is important to wash the hands immediately (unless the hands are the area being treated). No specific instruction is provided in the patient information regarding reapplying the product immediately after washing the treated area.

Q: Are there foods that are mentioned to interact with Локоид?

Official guidance indicates that one can eat and drink as normal while using the cream, ointment, or lotion. This indicates no specific food or drink restrictions are noted in the guidance for this topical medication.

Q: What does the package insert say about sharing Локоид with others?

Official patient information explicitly states that this medicine has been prescribed for the individual only. The labeling advises against sharing the product.

Q: Can Локоид cause a burning sensation when first applied?

Yes, regulatory information states that a stinging, burning, or irritation sensation at the application site is a common side effect. These application site reactions may occur when the medication is first applied to the skin.

Q: Are there differences in how Локоид is used for adults compared to children?

Yes, official regulatory regimens often differ for pediatric patients. Treatment for children is typically restricted to a shorter maximum duration (e.g., up to 7 days for infants) and may involve a lower application frequency compared to the adult regimen.

Q: Is it true that Локоид can sometimes make skin infections worse?

Yes, official warnings state that the use of topical corticosteroids, including this drug, may delay healing or worsen concomitant skin infections. If a skin infection is suspected or develops, an appropriate antimicrobial agent should be used alongside the steroid.

Q: How is the safety of Локоид monitored after it is released to the public?

Safety is monitored through post-marketing surveillance activities conducted by manufacturers and regulatory bodies. This involves collecting and reviewing reports of adverse events from the public and healthcare professionals to ensure the medicine's ongoing safety profile after its release.

Q: Is there a maximum weekly or daily amount of Локоид that is mentioned in the regulatory information?

While regulatory information provides guidance on daily application frequency and duration, the label does not typically provide a total maximum amount by weight (grams or ounces). Instead, patient guidance sometimes references a measurement system called Fingertip Units (FTUs) to help control the amount applied.

Q: Does the package insert for Локоид mention alcohol consumption?

Official guidance indicates that one can drink as normal while using hydrocortisone cream, ointment, or lotion. This suggests there is no known specific contraindication or interaction regarding moderate alcohol consumption with this topical formulation.

Q: Is there any research on the long-term use of Локоид?

Official research summaries note that the majority of core efficacy studies are short-term, typically lasting only two to four weeks. Studies focusing on extended use generally center on monitoring physiological markers, such as the HPA axis, rather than continuous efficacy over many months.

Q: Is it normal for the skin to feel slightly drier after using Локоид for a while?

Official information lists dryness at the application site as a possible local side effect. This reaction may be experienced when the medication is first applied to the skin or can occur over the course of use.

Q: Do studies exist that examine the use of Локоид in older adults?

Research overviews confirm that dedicated data for older adults remain insufficient or limited. However, some clinical trials that focus on corticosteroid-responsive dermatoses have included outpatients which may encompass a wide range of adult ages.

How to Store and Dispose of Локоид (Hydrocortisone Butyrate)

Локоид must be stored according to regulatory specifications to maintain product stability and ensure household safety.

---

Storage Requirements

Requirement Type	Official Condition
Temperature	Store at controlled room temperature between 20 C and 25 C (68 F and 77 F). Do not freeze.
Container Rule	Keep in the original container and ensure the tube is tightly closed after each use.
Child Safety	Must be kept out of the reach and sight of children.

---

Disposal Instructions

Unused or expired Локоид should not be disposed of by flushing it down the toilet or pouring it into a drain unless specific local instructions advise otherwise. Follow the guidance of a pharmacist or local waste disposal company regarding take-back programs or safe disposal procedures for unused medicine.